AAAAAA

   
Results: 1-11 |
Results: 11
Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience
Authors: Stivanello, M Berruti, A Torta, M Termine, A Tampellini, M Gorzegno, G Angeli, A Dogliotti, L
Citation: M. Stivanello et al., Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience, ANN ONCOL, 12, 2001, pp. S73-S77
The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: Comparison with standard subcutaneous octreotide therapy
Authors: Dogliotti, L Tampellini, M Stivanello, A Gorzegno, G Fabiani, L
Citation: L. Dogliotti et al., The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: Comparison with standard subcutaneous octreotide therapy, ANN ONCOL, 12, 2001, pp. S105-S109
Potential clinical value of circulating chromogranin A in patients with prostate carcinoma
Authors: Berruti, A Dogliotti, L Mosca, A Gorzegno, G Bollito, E Mari, M Tarabuzzi, R Poggio, M Torta, M Fontana, D Angeli, A
Citation: A. Berruti et al., Potential clinical value of circulating chromogranin A in patients with prostate carcinoma, ANN ONCOL, 12, 2001, pp. S153-S157
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretrested metastatic breast cancer patients. A multicenter phase II trial
Authors: Donadio, M Manzin, E Berruti, A Bottini, A Gorzegno, G Danese, S DeFabiani, E Sarobba, MG Lorusso, V Castiglione, F Moro, G Bertetto, O Bumma, C Dogliotti, L
Citation: M. Donadio et al., Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretrested metastatic breast cancer patients. A multicenter phase II trial, CANC CHEMOT, 47(5), 2001, pp. 391-396
Effects of the somatostatin analog lanreotide on the circulating levels ofchromogranin-A, prostate-specific antigen, and insulin-like growth factor-I in advanced prostate cancer patients
Authors: Berruti, A Dogliotti, L Mosca, A Tarabuzzi, R Torta, M Mari, M Gorzegno, G Fontana, D Angeli, A
Citation: A. Berruti et al., Effects of the somatostatin analog lanreotide on the circulating levels ofchromogranin-A, prostate-specific antigen, and insulin-like growth factor-I in advanced prostate cancer patients, PROSTATE, 47(3), 2001, pp. 205-211
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients
Authors: Bottini, A Berruti, A Bersiga, A Brizzi, MP Brunelli, A Gorzegno, G DiMarco, B Aguggini, S Bolsi, G Cirillo, F Filippini, L Betri, E Bertoli, G Alquati, P Dogliotti, L
Citation: A. Bottini et al., p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients, CLIN CANC R, 6(7), 2000, pp. 2751-2758
Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment
Authors: Berruti, A Dogliotti, L Osella, G Cerutti, S Reimondo, G Martino, A Gorzegno, G Catolla, R Angeli, A
Citation: A. Berruti et al., Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment, ONCOL REP, 7(4), 2000, pp. 777-781
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines
Authors: Berruti, A Sperone, P Bottini, A Gorzegno, G Lorusso, V Brunelli, A Botta, M Tampellini, M Donadio, M Mancarella, S De Lena, M Alquati, P Dogliotti, L
Citation: A. Berruti et al., Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines, J CL ONCOL, 18(19), 2000, pp. 3370-3377
Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline
Authors: Berruti, A Dogliotti, L Bitossi, R Fasolis, G Gorzegno, G Bellina, M Torta, M Porpiglia, F Fontana, D Angeli, A
Citation: A. Berruti et al., Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline, J UROL, 164(4), 2000, pp. 1248-1253
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases
Authors: Berruti, A Dogliotti, L Gorzegno, G Torta, M Tampellini, M Tucci, M Cerutti, S Frezet, MM Stivanello, M Sacchetto, G Angeli, A
Citation: A. Berruti et al., Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases, CLIN CHEM, 45(8), 1999, pp. 1240-1247
Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience
Authors: Berruti, A Borasio, P Gerbino, A Gorzegno, G Moschini, T Tampellini, M Ardissone, F Brizzi, MP Dolcetti, A Dogliotti, L
Citation: A. Berruti et al., Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience, BR J CANC, 81(5), 1999, pp. 841-845
Risultati: 1-11 |